Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10745318 | 0.87 | GAA (0.45) | ALOX5GAARAB9AMAPTCES2 | |
| SCHEMBL4348669 | 0.83 | ALOX5 (0.46) | ALOX5GAARAB9AMAPTCES2 | |
| SCHEMBL5298683 | 0.75 | ALOX5 (0.42) | ALOX5GAARAB9AMAPTCES2 | |
| SCHEMBL467496 | 0.75 | — | — | |
| SCHEMBL11329381 | 0.74 | — | — | |
| SCHEMBL79717 | 0.74 | — | — | |
| SCHEMBL2030838 | 0.74 | ALOX5 (0.47) | ALOX5GAARAB9AMAPTCES2 | |
| Ammonia Solution, Strong SCHEMBL355659 | 0.72 | — | — | |
| SCHEMBL8587037 | 0.72 | — | — | |
| SCHEMBL28899436 | 0.71 | LMNA (0.43) | ALOX5MAPTTSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110087028-A1 | METHOD FOR PREPARING CLOPIDOGREL AND ITS DERIVATIVES | ENZYTECH LTD. (KR) | 2011-04-14 | — | — | US | disclosed |
| EP-2298777-A2 | METHOD FOR PREPARING CLOPIDOGREL AND ITS DERIVATIVES | Enzytech, Ltd. (KR) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087028-A1 | METHOD FOR PREPARING CLOPIDOGREL AND ITS DERIVATIVES | PTGIS, PLA2G7, PTGIR | ALOX5 75/4885GAA 860/4885RAB9A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.